List of Auvelity drug patents
Auvelity is owned by Axsome.
Auvelity contains Bupropion Hydrochloride; Dextromethorphan Hydrobromide.
Auvelity has a total of 103 drug patents out of which 0 drug patents have expired.
Auvelity was authorised for market use on 18 August, 2022.
Auvelity is available in tablet, extended release;oral dosage forms.
Auvelity can be used as dextromethorphan and bupropion in combination to treat major depressive disorder.
The generics of Auvelity are possible to be released after 07 January, 2040.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8569328 | AXSOME | Compositions and methods comprising tilidine or related compounds and dextromethorphan |
Oct, 2033
(10 years from now) | |
| US11364233 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11357744 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(11 years from now) | |
| US9474731 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US9421176 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11311534 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10898453 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11433067 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9457023 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11096937 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10966941 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11298351 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11090300 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10894047 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11534414 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11517542 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11517543 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11541048 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11541021 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10786469 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10881657 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10874663 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10799497 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
| US11058648 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10864209 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10806710 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10786496 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11020389 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11185515 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10945973 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10596167 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11439636 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11426401 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10772850 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11253491 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10548857 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11229640 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
| US10874665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10933034 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US10894046 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11191739 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10874664 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11197839 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11147808 | AXSOME | Method of decreasing the fluctuation index of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11141416 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11141388 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11213521 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11129826 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11123343 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10966974 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10105327 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11510918 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
| US11478468 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11497721 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
| US11524008 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11524007 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10780064 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US10966942 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US10940124 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US10925842 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUVELITY family patents
198
United States
15
China
12
Australia
11
Korea, Republic of
10
Japan
9
Canada
9
European Union
8
Israel
8
Singapore
8
New Zealand
3
Mexico
3
Costa Rica
3
Brazil
3
Peru
3
Ecuador
2
Colombia
2
Malaysia
2
Chile
1
Denmark
1
Hong Kong
1
Slovenia
1
Lithuania
1
Hungary
1
Morocco
1
Croatia
1
Portugal
1
Spain
1
Poland
1
RS
1
Nicaragua
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic